NTRK Gene Fusions | Clinical

FDA Clears Phase 1/2 Study of ABT-101 in Non–Small Cell Lung Cancer

September 14, 2022

The FDA has granted approval for an investigational new drug protocol amendment for ABT-101, a mutant selective tyrosine kinase inhibitor which has shown superior selectivity against HER2 exon 20 mutations in NSCLC in preclinical studies.

Larotrectinib Exhibits Rapid and Sustained HRQoL Improvement in TRK Fusion Cancers

June 07, 2022

Continued robust quality of life improvement documented in an expanded dataset of patients with TRK fusion cancer treated with larotrectinib are consistent with the rapid onset of clinical benefit and favorable safety profile of larotrectinib in both adult and pediatric patients.